Specialty Pharmacy Analytics for PE-Backed Pharmacies
The economics of every fill, seen in one place
Specialty pharmacy, infusion and compounding are active private equity territory. Whether a roll-up pays off depends on economics tangled together in every prescription.
We have done this work inside a PE-backed national pharmacy specializing in fertility medications, cutting costs about 40% in a core part of the business and lifting customer retention 10% in a month, and on the manufacturer side of rebate contracts.
Four layers between the drug and the margin
Each layer is set by a different party and moves on its own.
Acquisition cost
Which location is the cheapest place to fill each order, once shipping is counted?
Reimbursement
How much of what payers and PBMs pay survives the fees that arrive after the fill?
Manufacturer programs where we've gone deepest
Which therapy lines sit just short of a rebate threshold, and what is crossing it worth?
Cost to dispense and serve
What do clinical time, shipping, cold chain and chasing what's owed really cost per patient?
Proven in fertility, built on mechanics every specialty pharmacy shares
Rebate strategy to reach manufacturer market-share thresholds.
Drug-cost economics: one source of truth on acquisition cost.
Dispensing analytics by patient type and referring clinic.
The same mechanics apply anywhere threshold-based programs, variable acquisition cost and referral-driven volume meet.
Oncology, rare disease and infusion differ in payer mix, limited-distribution access and clinical program requirements. Those are the first things we test, before assuming any result repeats.
See the margin in every layer
A conversation is the fastest way to see what this would show in your pharmacy.